Johnson & Johnson stock
Price history
+46.35% over the period1 year: from $195.25 (November 13, 2025) to $285.75 (November 13, 2026), +46.35%.
Show chart data
Closing prices adjusted for splits: the last close of each month.
| Date | Close |
|---|---|
| November 13, 2026 | $285.75 |
| October 30, 2026 | $273.20 |
| September 30, 2026 | $264.74 |
| August 31, 2026 | $265.85 |
| July 31, 2026 | $256.35 |
| June 30, 2026 | $253.97 |
| May 29, 2026 | $225.33 |
| April 30, 2026 | $229.85 |
| March 31, 2026 | $244.44 |
| February 27, 2026 | $248.43 |
| January 30, 2026 | $227.25 |
| December 31, 2025 | $206.95 |
| November 28, 2025 | $206.92 |
| November 13, 2025 | $195.25 |
At a glance
The company
Researches, develops, manufactures and sells a broad range of healthcare products including pharmaceuticals and medical devices
Latest results
Quarter to September 30, 2026 · EPS $2.59 (estimate $2.53)
Next event
Dividend
TickerLandia's take on Johnson & Johnson
- Priced as usual relative to earnings: P/E on the latest fiscal year 26 vs a median of 24 over its last 10 fiscal years.
- Priced in line with similar companies: trailing 12-month P/E 43 vs 42 (+2%) in a group of 10.
- Strong point: Market momentum (81/100 in its group). Weak point: Growth (29/100).
Analysis calculated by TickerLandia from financial statements and prices, with public rules. Not investment advice. How we analyse stocks
Where the price stands
−0.82% from the 52-week high
Analysts · 23 analysts
Average target$279.41−2.22% vs. price
Buy 16 · Hold 6 · Sell 1 · Buy
TickerLandia Fingerprint: Johnson & Johnson
Compared with similar companies: very low risk, very high price, and very strong momentum.
Financials and price compared with 25 companies in the drug manufacturers - general industry, worldwide. Momentum and risk compared with 883 North American stocks.
Pricevery high85
How much it costs relative to what it produces.
Metric Value Position in group P/E (trailing 12 months) 43.4 80 Forward P/E 24.6 90 EV/EBITDA 20.7 94 Price/book 8.44 77 Price/sales 6.92 86 Profitabilitylow38
How much it earns on revenue and capital.
Metric Value Position in group Gross margin 67.8% 18 Net margin 16.2% 54 ROE 20.0% 44 ROA 8.5% 34 Operating margin 26.6% 38 Earnings stabilityhigh72
How steady its margins were over the last five annual reports.
Metric Value Position in group Margin variabilitycounts in reverse: lower means more earnings stability 1.0% 90 Loss-making yearscounts in reverse: lower means more earnings stability 0 of 5 annual reports 54 Growthlow29
How fast revenue and earnings are growing.
Metric Value Position in group Revenue growth (year over year) +5.90% 34 Earnings growth (year over year) −95.90% 2 Average revenue growth (3 years) +5.60% 50 Financial strengthaverage54
How well it would weather a hard period: debt, liquidity, interest.
Metric Value Position in group Net debt/EBITDAcounts in reverse: lower means more financial strength 0.68 66 Current ratio 1.02 22 Interest coverage 27.1 66 Debt/equitycounts in reverse: lower means more financial strength 0.55 60 Dividendhigh65
How much it returns to shareholders, and for how long.
Metric Value Position in group Dividend yield 1.9% 31 Consecutive dividend years at least 37 years 90 Payout ratio 80.1% 73 Market momentumvery strong81
How the stock has moved compared with the market.
Metric Value Position in group Distance from 200-day average +14.40% 79 Relative strength (3 months) +12.45% 79 Relative strength (6 months) +22.09% 81 1-year return +46.35% 86 Riskvery low12
How much the price swings.
Metric Value Position in group Volatility (60 days) 24.3% 22 Beta (1 year) −0.07 13 Maximum drawdown (12 months) 11.0% 2
Position in the group from 0 to 100 (100 = highest value): it describes, it does not rate. Tap a row for the metrics. Calculated on November 16, 2026. An indicator calculated by TickerLandia from financial statements and market data. How it is calculated
Valuation
Johnson & Johnson is priced as in the past and in line with similar companies
On the latest fiscal year's earnings (2025), Johnson & Johnson's P/E today is 25.9, in line with the median of its last 10 fiscal years (23.9; between 11.4 and 297.3 from 2016 to 2025). Johnson & Johnson's P/E (trailing 12 months): 43.4, in line with the median of a group of 10 similar companies (42.3).
Compared with 10 similar companies
| Metric | Johnson & Johnson | Position in the group | Band |
|---|---|---|---|
| P/E (trailing 12 months) | 43.4 | Middle | |
| Forward P/E | 24.6 | High | |
| Operating margin | 26.6% | Low | |
| ROE | 20.0% | Middle | |
| Debt/equity | 0.55 | Low |
P/E at fiscal year end; today on the latest fiscal year's earnings. Grey band: the middle half of the group; tick: the median; dot: Johnson & Johnson. All multiples and dividends
TickerLandia analysisHow it is calculated
The financials
The business in numbers
Revenue
$25.4B
Latest quarter · Q3 2026
Net income
$210M
Latest quarter · Q3 2026
Quarterly net margin
0.8%
Latest quarter · Q3 2026
Numbers and valuation
Full valuation- Market cap
- $687.89B
- P/E
- 43.4
- EPS
- $6.59
- Volume
- 6.28M
- Daily trading
- €1.83B
- Dividend yield
- 1.85%
How Johnson & Johnson is changing
All resultsRevenue grew 2.7% a year on average over the last 5 years
Free cash flow equal to 76% of net income
Shares outstanding down 9.0% in 5 years
Returns
Johnson & Johnson returns with dividends
$1,000 invested in Johnson & Johnson 5 years ago, on November 15, 2021, would be worth $2,009 today with dividends reinvested: +100.89% in total, +14.99% per year. On price alone it would be $1,747 (+74.75%).
| Period | Johnson & Johnson | S&P 500 | $1,000 becomes |
|---|---|---|---|
| 1 month | +14.94% | −3.12% | $1,149 |
| 6 months | +24.01% | +1.58% | $1,240 |
| Year to date | +38.08% | +10.46% | $1,381 |
| 1 year | +49.64% | +12.23% | $1,496 |
| 3 years | +110.77% | +71.41% | $2,108 |
| 5 years | +100.89% | +61.48% | $2,009 |
| 10 years | +221.57% | +249.40% | $3,216 |
Over the last 6 months it has done better than 60% of the stocks in the Healthcare sector.
From 1 year up with dividends reinvested, before taxes; under a year price only. S&P 500: price only. Calculate your investment
The chart in detail
Johnson & Johnson: technical analysis
Johnson & Johnson is in an uptrend: the price is above its 50- and 200-session moving averages, and the 200-session average is rising. The price is at its highest close since January 2, 1990.
- Trend
- Upward
- RSI (14 sessions)
- 66
- Between 30 and 70
- vs 200-session average
- +14.40%
Active signals
New 52-week high.
since November 12, 2026
Support and resistance
Price areas where Johnson & Johnson has stopped several times in the last year. They describe the chart; they are not forecasts.
- No resistance above: the price is near the highs of the year
- Last price$285.75
- Support$281.54−1.47%2 touches, last on October 30, 2026
- Support$275.53−3.58%3 touches, last on September 24, 2026
- Support$262.97−7.97%3 touches, last on October 12, 2026
Volatility and risk
Over the last year it has moved little with the S&P 500.
- Beta (1 year) vs S&P 500
- −0.07
- Volatility (60 sessions, annualised)
- 24.3%
- Largest fall in the last year
- −10.96%
Close of November 13, 2026. Descriptive data calculated on daily prices: it describes the chart and is not investment advice. Beta and volatility describe the last year and can change a lot from one year to the next. How we calculate it
Johnson & Johnson: seasonality
Average monthly price change over 37 years
Over the last 37 years, the strongest month for Johnson & Johnson has been April: +2.53% on average, positive in 21 years out of 37. The weakest has been February: −0.30% on average, positive in 20 years out of 37. November, the current month, has been positive in 22 years out of 36 (+1.72% on average).
Show chart data
| Month | Average | Median | Positive years |
|---|---|---|---|
| January | +0.03% | +0.61% | 19 of 36 |
| February | −0.30% | +0.22% | 20 of 37 |
| March | +1.34% | +1.35% | 22 of 37 |
| April | +2.53% | +1.01% | 21 of 37 |
| May | +0.06% | −0.52% | 18 of 37 |
| June | +0.87% | +1.30% | 19 of 37 |
| July | +1.86% | +2.46% | 24 of 37 |
| August | +0.14% | +0.25% | 19 of 37 |
| September | +0.36% | −0.12% | 18 of 37 |
| October | +2.32% | +2.06% | 26 of 37 |
| November | +1.72% | +0.67% | 22 of 36 |
| December | +0.99% | +1.34% | 25 of 36 |
Price change only, dividends excluded. Past seasonality does not predict future moves.
The company
Johnson & Johnson and its competitors
Sales are split between the United States, which generated 57.1% of revenue, and markets outside the US, which generated 42.9%. Johnson & Johnson researches, manufactures and sells healthcare products through two segments. Innovative Medicine supplies prescription drugs for oncology, immunology and neuroscience, as well as cardiovascular and metabolic conditions, pulmonary hypertension and infectious diseases, through retailers, wholesalers, hospitals and healthcare professionals.
- Headquarters
- New Brunswick, United States
- Employees
- 138,200
- Founded
- 1886
- Chief executive
- Joaquin Duato
| Company | Market cap | Operating margin | P/E (trailing 12 months) | 6 months |
|---|---|---|---|---|
| Johnson & JohnsonJNJ | $687.89B | 26.6% | 43.4 | +24.01% |
| AbbVieABBV | $521.5B | 36.6% | 50.6 | +41.50% |
| Eli Lilly andLLY | $1.29T | 51.3% | 46.9 | +42.11% |
| MerckMRK | $364.26B | 35.2% | 147.8 | +30.24% |
| AmgenAMGN | $251.89B | 34.1% | 27.0 | +38.41% |
| Gilead SciencesGILD | $208.48B | 38.2% | — | +26.33% |
Same industry or related industries, similar size. Compare Johnson & Johnson with its competitors · Full profile
More on Johnson & Johnson
- Johnson & Johnson revenue and financials
- Johnson & Johnson dividend and valuation
- Johnson & Johnson stock return
- Johnson & Johnson employees, headquarters and business
